Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. | Neoplasma;63(3): 471-6, 2016. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.

Fiala, O; Pesek, M; Finek, J; Racek, J; Minarik, M; Benesova, L; Bortlicek, Z; Sorejs, O; Kucera, R; Topolcan, O.

Neoplasma ; 63(3): 471-6, 2016.

Article in En | MEDLINE | ID: mdl-26952513

Subject(s)
Key words

EGFR-TKI; NSCLC; albumin; biomarker.; erlotinib; lung cancer; prediction

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serum Albumin / Carcinoma, Non-Small-Cell Lung / Erlotinib Hydrochloride / Lung Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Neoplasma Year: 2016 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serum Albumin / Carcinoma, Non-Small-Cell Lung / Erlotinib Hydrochloride / Lung Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Neoplasma Year: 2016 Document type: Article Country of publication: